Clinical Trial Update: To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors [Phase 1]

View source ↗

Summary

Phase 1 trial to evaluate tolerability and pharmacokinetics of TQB2101 in patients with advanced malignant tumors; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Colorectal Cancer
• Lung Cancer

Drugs mentioned

• TQB2101

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. | Conditions: Breast Cancer, Lung Cancer | Phase 1 | Status: NOT_YET_RECRUITING